A 2026 Italian study found daily espresso or moka pot drinkers had lower rates of MASLD (fatty liver disease), suggesting pressure-brewed coffee offers measurable liver-protective benefits.
Does Espresso or Moka Pot Coffee Protect Your Liver? What a New Italian Study Found
A new Italian study found that people who drink espresso or moka pot coffee daily are meaningfully less likely to develop metabolic dysfunction-associated steatotic liver disease (MASLD) — the condition formerly known as non-alcoholic fatty liver disease (NAFLD) — compared to those who do not drink these specific brew styles regularly.
The research, conducted among coffee drinkers in southern Italy and reported by Daily Coffee News, adds a significant new data point to the already substantial body of evidence linking habitual coffee consumption with liver health. What makes it particularly notable is its specificity: rather than simply asking "do you drink coffee?", it distinguishes how that coffee is brewed — and finds that the method matters.
Before getting into mechanisms and implications, here is a quick-reference comparison of the most common brewing methods discussed in liver-health research, measured against the key variables researchers believe drive the protective effect:
| Brewing Method | Pressure Used | Diterpene Content | Chlorogenic Acid Level | Filter Used? | Linked to Liver Protection in Studies? |
|---|---|---|---|---|---|
| Espresso | High (9 bar) | Moderate–High | High | No paper filter | Yes — new Italian study |
| Moka Pot | Low–Medium (1–2 bar) | Moderate–High | High | No paper filter | Yes — new Italian study |
| Drip / Filter Coffee | None (gravity) | Low (paper removes diterpenes) | Moderate | Yes (paper) | Yes, prior studies, but effect size debated |
| French Press / Plunger | None | High | Moderate | No | Limited direct liver data |
| Instant Coffee | None | Low–Moderate | Low–Moderate | Varies | Some association, weaker signal |
This is a comparative snapshot of brewing variables, not a clinical ranking — no single cup of coffee is a medical treatment. But the pattern it reveals is worth understanding for anyone thinking about their daily brew choices.
What exactly did the Italian study find?
The study examined a cohort of habitual coffee drinkers in southern Italy — a region where espresso and moka pot preparation are deeply embedded in daily culture — and assessed their rates of MASLD against their reported coffee consumption habits. Participants who drank espresso or moka pot coffee daily showed a statistically lower likelihood of developing MASLD compared to those who did not drink these styles regularly, as Daily Coffee News's coverage of the research details.
MASLD is the accumulation of excess fat in liver cells in people who drink little or no alcohol, typically in the context of metabolic risk factors such as obesity, type 2 diabetes, high blood pressure, or dyslipidaemia. It is one of the most prevalent liver conditions globally, affecting an estimated 25–30% of the world's adult population, and it can progress to liver fibrosis, cirrhosis, and hepatocellular carcinoma.
The study's geographic focus is scientifically useful. Southern Italy has a relatively homogeneous coffee culture — espresso and moka pot dominate, drip coffee is rare — which reduces the confounding noise that plagues multi-country coffee studies where brew method varies wildly alongside diet, genetics, and lifestyle. Studying a population where nearly everyone who drinks coffee drinks it the same way allows researchers to draw cleaner inferences about method-specific effects.
The study does not establish causation definitively. Observational research of this kind is hypothesis-generating rather than hypothesis-confirming — it identifies associations that warrant further investigation, ideally through randomised controlled trials. The biological plausibility of the finding is strong, however, which is why the research community is paying attention.
Why would espresso or moka pot specifically protect the liver?
The answer lies in the chemistry of unfiltered, pressure-brewed coffee. When hot water is forced through compacted coffee grounds under pressure — as in an espresso machine at roughly 9 bar, or a moka pot at 1–2 bar — it extracts a different chemical profile than gravity-fed drip brewing through a paper filter.
Two categories of compounds are particularly relevant.
Chlorogenic acids (CGAs) are polyphenolic antioxidants found in high concentrations in coffee. They form a family of esters between certain trans-cinnamic acids and quinic acid, and rank among the most abundant dietary antioxidants in the human diet. Espresso and moka pot brewing extract CGAs efficiently due to the combination of pressure, heat, and the absence of a paper filter that might adsorb some of these compounds. Multiple studies have shown that CGAs reduce hepatic fat accumulation, improve insulin sensitivity, and reduce oxidative stress in liver tissue — all mechanisms directly relevant to MASLD prevention.
Diterpenes — specifically cafestol and kahweol — are lipid-soluble compounds found in coffee oil. They are present in high concentrations in unfiltered brews (espresso, moka pot, French press) and are largely removed by paper filters in drip coffee. Diterpenes have a well-documented effect of raising LDL cholesterol at high doses, which is why filtered coffee is sometimes recommended for people with cardiovascular risk. They also have potent anti-inflammatory and hepatoprotective properties. Cafestol in particular has been shown in animal and cell studies to activate nuclear receptors involved in bile acid regulation and to reduce liver fat accumulation. The Italian study's focus on espresso and moka pot — both unfiltered, high-diterpene brews — aligns with this mechanism.
The combination of high CGAs and intact diterpenes in espresso and moka pot may create a synergistic hepatoprotective effect that filtered coffee partially loses when the paper strip removes the coffee oils.
How does MASLD develop, and why does this matter for Indian coffee drinkers?
MASLD spans a spectrum of liver conditions ranging from simple steatosis (fat accumulation without inflammation) through metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, and ultimately cirrhosis. Insulin resistance, excess caloric intake, sedentary behaviour, and genetic predisposition all drive the condition.
India has a significant and growing MASLD burden. Studies published in Indian medical journals estimate that MASLD affects between 9% and 32% of the Indian population depending on the cohort studied, with urban populations and people with type 2 diabetes at substantially higher risk. The Indian subcontinent also carries a genetic predisposition — the PNPLA3 gene variant associated with higher MASLD risk is more prevalent in South Asian populations than in European ones.
Against this backdrop, the Italian study's findings matter beyond their Mediterranean context. South India in particular has a strong filter coffee tradition — the iconic South Indian filter coffee is brewed through a metal two-chamber device that, like the moka pot, does not use a paper filter, though the brewing mechanism differs (gravity drip through a metal filter rather than pressure). Whether South Indian filter coffee confers similar benefits to espresso and moka pot is an open research question, but the absence of a paper filter and the resulting retention of coffee oils suggests there may be meaningful overlap.
North Indian coffee culture is more varied — instant coffee, café-style espresso drinks, and cold brew all have significant market share — and the hepatoprotective signal may be weaker or less consistent in populations whose primary coffee format is instant or heavily diluted with milk and sugar.
Is all coffee good for the liver, or only espresso and moka pot?
Before this Italian study, the broader coffee-liver literature was largely method-agnostic. A landmark 2017 meta-analysis in the British Medical Journal found that drinking two cups of coffee per day was associated with a 44% lower risk of liver cirrhosis compared to drinking no coffee, and a 2021 review in Alimentary Pharmacology & Therapeutics found consistent inverse associations between coffee consumption and MASLD risk across multiple study designs and populations.
Most of those earlier studies did not distinguish brew method — they simply asked participants how many cups they drank per day. The Italian study adds granularity: among coffee types, espresso and moka pot show a particularly strong signal.
This does not mean drip coffee or instant coffee offer no benefit. The existing literature suggests they do. But the magnitude of the effect may differ. Filtered coffee removes diterpenes, which may reduce the hepatoprotective signal. Instant coffee has lower concentrations of both CGAs and diterpenes than freshly brewed coffee. The Italian study's finding is best interpreted as: within the coffee category, brewing method influences the strength of the liver-protective association.
For consumers, this is a nuanced message. Switching from no coffee to any coffee is likely more impactful for liver health than switching from drip to espresso. But for people who already drink coffee daily and want to optimise their brew choice for health, the Italian study suggests espresso or moka pot may be the better option — all else being equal.
What are the limitations of this study?
Honest science communication requires acknowledging what this study does not prove.
It is observational. Observational research cannot establish that espresso or moka pot coffee causes lower MASLD rates — only that the two are associated. People who drink espresso daily in southern Italy may differ from non-drinkers in other ways (diet quality, social activity, stress levels, healthcare access) that the researchers could not fully control for.
The study population is also geographically and culturally specific. Southern Italians follow a Mediterranean diet, have relatively high physical activity, and have a specific genetic background. The findings may not translate directly to populations with different dietary patterns, metabolic baselines, or genetic profiles — including Indian populations.
Dose and preparation details matter too. The study does not appear to specify exactly how many cups per day constitute "daily" consumption, whether milk and sugar were added, or what coffee bean varieties and roast levels were used. Roast level significantly affects CGA content — lighter roasts retain more CGAs than dark roasts, because the roasting process degrades chlorogenic acids. If the southern Italian espresso drinkers in this study were predominantly drinking medium-roast coffee, the findings may not apply to people drinking very dark espresso roasts.
Finally, the study does not address people with existing liver disease. The association found is for prevention of MASLD in people without established liver disease. Anyone with existing liver conditions should consult their hepatologist before making dietary changes based on this research.
How much coffee would you need to drink to see a benefit?
The Italian study does not specify an exact dose-response curve, but the broader coffee-liver literature offers some guidance. Most studies showing liver-protective effects have found the association strongest at two to four cups per day. Below two cups, the signal weakens; above four to five cups, the incremental benefit plateaus and the risk of other adverse effects — anxiety, sleep disruption, cardiovascular effects in sensitive individuals — increases.
A standard Italian espresso is roughly 25–30 ml with approximately 60–70 mg of caffeine. Two to four espressos per day — a common consumption pattern in southern Italy — would deliver 120–280 mg of caffeine, well within the 400 mg daily limit that most health authorities consider safe for healthy adults.
Moka pot coffee is typically brewed in larger volumes (a standard 3-cup moka pot produces roughly 150–200 ml) and has a caffeine concentration between espresso and drip coffee. Two to three moka pot servings per day would likely fall in a similar hepatoprotective range.
The key caveat is that these estimates assume black coffee or coffee with small amounts of milk. Adding large quantities of sugar, flavoured syrups, or full-fat cream substantially changes the metabolic profile of the drink and could offset the liver-protective benefits — particularly in people with insulin resistance or metabolic syndrome, who are already at elevated MASLD risk.
Should you switch your brewing method based on this study?
For most healthy adults who already drink coffee, the Italian study provides modest but real support for choosing espresso or moka pot over heavily filtered or instant alternatives — particularly if liver health is a concern. The evidence is not strong enough to constitute a clinical recommendation, but it is coherent with the existing mechanistic literature and adds a new population-level data point.
For people who do not currently drink coffee, this study is not a reason to start. The liver-health benefits of coffee are best understood as a modifier of risk in people who already consume it, not as a therapeutic intervention. Starting to drink coffee specifically for liver health — especially with cardiovascular risk factors, given diterpenes' LDL-raising potential — should be discussed with a doctor.
For Indian consumers, the study raises interesting questions about South Indian filter coffee, a brew that shares the unfiltered, metal-filter characteristic of moka pot brewing. If you already drink South Indian filter coffee daily, the biological rationale for a similar hepatoprotective effect is plausible, though direct evidence is lacking.
Coffee is not the only dietary lever for liver health, either. If you are interested in functional beverages that support metabolic wellbeing, our guide to best herbal immune support teas and functional blends covers several options — including milk thistle and dandelion root teas — that have their own evidence base for liver support. And if caffeine is a concern, our roundup of caffeine-free Asian herbal teas for sleep and a restless mind offers alternatives that won't interfere with your sleep architecture.
What does this mean for the broader coffee and health conversation?
The Italian study is part of a growing body of research moving the coffee-health conversation from "is coffee good or bad?" to "which coffee, how much, and for whom?" — a more useful frame for consumers and clinicians alike.
Coffee is a complex mixture of hundreds of bioactive compounds whose health effects depend on bean variety, roast level, grind size, water temperature, brewing time, pressure, and filtration method. The idea that all coffee is equivalent — that a vending-machine instant coffee and a freshly pulled espresso are interchangeable from a health perspective — is not supported by the evidence.
The Italian study's contribution is to anchor this nuance in a real-world population study rather than a laboratory model. Southern Italian espresso culture, with its emphasis on small, concentrated, unfiltered shots consumed multiple times daily, turns out to be a natural experiment in the hepatoprotective effects of pressure-brewed coffee. The results are encouraging.
For the global coffee community — including India's rapidly growing specialty coffee market — this research reinforces the value of quality brewing. Espresso machines and moka pots are not just about taste; they may be delivering a meaningfully different biochemical payload than a paper-filtered drip or a spoonful of instant powder.
The next step for researchers would be a prospective cohort study or, ideally, a randomised controlled trial comparing liver biomarkers (ALT, AST, liver fat fraction measured by MRI) across different brewing methods in a controlled population. Until that evidence exists, the Italian study is a well-designed observational signal pointing in a clear direction: if you drink coffee for your liver, brew it under pressure, skip the paper filter, and drink it black or close to it.
The bottom line
Daily consumption of espresso or moka pot coffee is associated with a lower likelihood of developing MASLD, according to a new study of southern Italian coffee drinkers. The biological mechanisms — high chlorogenic acid content, intact diterpenes, and the absence of paper filtration — are plausible and consistent with prior laboratory and epidemiological research.
The study does not prove causation, does not establish an exact protective dose, and cannot be directly extrapolated to all populations. But it adds meaningful specificity to the coffee-liver story: among brew methods, unfiltered pressure brewing appears to carry the strongest hepatoprotective signal.
For Indian consumers who already drink coffee, this is a gentle nudge toward espresso or moka pot — or reason to consider whether your South Indian filter coffee habit might be doing your liver a quiet favour. For those managing metabolic risk factors, it is a conversation worth having with your doctor.